Search results
Results from the WOW.Com Content Network
Lymphangiosarcoma is a rare cancer which occurs in long-standing cases of primary or secondary lymphedema (swelling due to lymphatic system obstruction). It involves either the upper or lower lymphedematous extremities but is most common in upper extremities. [1]
It may also occur in the lower limbs or groin after surgery for colon, ovarian or uterine cancer, if removal of lymph nodes or radiation therapy is required. Surgery or treatment for prostate, colon and testicular cancers may result in secondary lymphedema, particularly when lymph nodes have been removed or damaged. [medical citation needed]
Chemo may also be used in more advanced cases to control the symptoms and side effects of the cancer. [1] After surgery to remove the tumor, a single dose of chemotherapy injected into the bladder is helpful in reducing the rate of cancer recurrence in people who have cancer of the inner lining of the bladder (upper tract urothelial carcinoma ...
Edema (American English), also spelled oedema (British English), and also known as fluid retention, dropsy and hydropsy, is the build-up of fluid in the body's tissue, [1] a type of swelling. [4] Most commonly, the legs or arms are affected. [1] Symptoms may include skin that feels tight, the area feeling heavy, and joint stiffness. [1]
Bladder cancer is most common in wealthier regions of the world, where exposure to certain carcinogens is highest. It is also common in places where schistosome infection is common, such as North Africa. [47] Bladder cancer is much more common in men than women; around 1.1% of men and 0.27% of women develop bladder cancer. [2]
Medicare covers treatment and services for bladder cancer; however, you may still have significant out-of-pocket costs depending on factors like recommended treatment or the stage of your cancer.
A study led by Mayo Clinic found a “widening gap between lifespan and healthspan" among 183 countries. The lead researcher and another doctor discuss the drivers of poor health late in life.
The outcome depends on the subtype, with some being curable and treatment prolonging survival in most. [9] The five-year survival rate in the United States for all Hodgkin lymphoma subtypes is 85%, [4] while that for non-Hodgkin lymphomas is 69%. [15] Worldwide, lymphomas developed in 566,000 people in 2012 and caused 305,000 deaths. [16]